ArticleBioengineering (Basel, Switzerland)2026
Design and Development of Rehabi, a mHealth Telerehabilitation Platform with Markerless Motion Analysis.
Article in Bioengineering (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis affect millions worldwide and are projected to rise sharply by 2050, highlighting the importance of scalable telerehabilitation. This paper introduces Rehabi, a mobile, user-friendly tele-rehabilitation platform that centrally integrates markerless motion for biomechanical assessment and monitoring. Rehabi development followed a user-centered methodology, combining questionnaires, interviews, and natural language processing to elicit requirements from patients and clinicians. The system architecture was implemented in accordance with Clean Architecture principles to ensure modularity and scalability. In a pilot clinical validation of the markerless motion algorithm integrated into Rehabi, 14 post-arthroplasty patients showed moderate agreement for hip flexion (ICC = 0.686) and good agreement for knee flexion (ICC = 0.801). Although the sample was small, the results show a promising trend suggesting that mobile markerless motion capture may be a viable option for remote assessment and monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.